Evidence map›Paper›PMID 34261517›Full record

ArticleGenome medicine2021

Haplotype-resolved germline and somatic alterations in renal medullary carcinomas.

Kar-Tong Tan, Hyunji Kim, Jian Carrot-Zhang, Yuxiang Zhang, Won Jun Kim, Guillaume Kugener, Jeremiah A Wala, Thomas P Howard, Yueh-Yun Chi, Rameen Beroukhim and 8 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. The Bioinformatic Applications of Hi-C and Linked Reads.Genomics, proteomics & bioinformatics · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Recent Advances in Renal Medullary Carcinoma.International journal of molecular sciences · 2022
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 1 country.

Kar-Tong TanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hyunji KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jian Carrot-ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yuxiang ZhangDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Won Jun KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Guillaume KugenerBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Jeremiah A WalaDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Thomas P HowardDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yueh-Yun ChiDepartment of Pediatrics, University of Southern California, Los Angeles, CA, USA.
Rameen BeroukhimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Heng LiBiostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gavin HaPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Seth L AlperDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Elizabeth J PerlmanDepartment of Pathology, Northwestern University, Chicago, IL, USA.
Elizabeth A MullenDepartment of Hematology and Oncology, Boston Children's Hospital, Boston, MA, USA.
William C Hahn *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. william_hahn@dfci.harvard.edu.
Matthew Meyerson *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. matthew_meyerson@dfci.harvard.edu.
Andrew L Hong *Department of Pediatrics, Emory University, Atlanta, GA, USA. andrew.hong2@emory.edu.
Broad Institute · USDana-Farber Cancer Institute · USHarvard University · USBeth Israel Deaconess Medical Center · USCenter for Cancer and Blood Disorders · USFred Hutch Cancer Center · USNorthwestern University · USUniversity of California, San Francisco · USUniversity of Southern California · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5M
COG U24 Funding 2026-2027U24CA196173 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Mignon Lee-Cheun Loh, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$62.5M
Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Support for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5M
The Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8M
NCI NIH HHS U01 CA176058NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA114766NCI NIH HHS U24 CA196173NIGMS NIH HHS T32 GM007739NIGMS NIH HHS T32 GM007753
6 · The paper itself

Abstract

backgroundRenal medullary carcinomas (RMCs) are rare kidney cancers that occur in adolescents and young adults of African ancestry. Although RMC is associated with the sickle cell trait and somatic loss of the tumor suppressor, SMARCB1, the ancestral origins of RMC remain unknown. Further, characterization of structural variants (SVs) involving SMARCB1 in RMC remains limited.

methodsWe used linked-read genome sequencing to reconstruct germline and somatic haplotypes in 15 unrelated patients with RMC registered on the Children's Oncology Group (COG) AREN03B2 study between 2006 and 2017 or from our prior study. We performed fine-mapping of the HBB locus and assessed the germline for cancer predisposition genes. Subsequently, we assessed the tumor samples for mutations outside of SMARCB1 and integrated RNA sequencing to interrogate the structural variants at the SMARCB1 locus.

resultsWe find that the haplotype of the sickle cell mutation in patients with RMC originated from three geographical regions in Africa. In addition, fine-mapping of the HBB locus identified the sickle cell mutation as the sole candidate variant. We further identify that the SMARCB1 structural variants are characterized by blunt or 1-bp homology events.

conclusionsOur findings suggest that RMC does not arise from a single founder population and that the HbS allele is a strong candidate germline allele which confers risk for RMC. Furthermore, we find that the SVs that disrupt SMARCB1 function are likely repaired by non-homologous end-joining. These findings highlight how haplotype-based analyses using linked-read genome sequencing can be applied to identify potential risk variants in small and rare disease cohorts and provide nucleotide resolution to structural variants.

Indexed as

AllelesGerm-Line MutationHaplotypesMutationCarcinoma, MedullaryCell Line, TumorChildChild, PreschoolComputational BiologyDatabases, GeneticDNA BreaksFemaleGene Expression Regulation, NeoplasticGenetic Association StudiesGenetic Predisposition to DiseaseGenomicsOncogene Proteins, FusionHaplotypesLinked-read sequencingRenal medullary carcinomaSickle cell trait

Identifiers

PMID34261517
PMCPMC8281718
OpenAlexW3180211998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.